Menu
  • About RedHill
  • Products
  • Partnering
  • Investors
  • News
  • Contact
  • CAREERS
  • Press Releases

     
    Press Releases
      Date Summary View
    Jun 6, 2017
    TEL-AVIV, Israel, June 06, 2017 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (NASDAQ:RDHL) (Tel-Aviv Stock Exchange:RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company primarily focused on the development and commercialization of late clinical-stage, proprietary, orally-administered, small molecule drugs for gastrointestinal a...
    PDF
    May 4, 2017
    TEL-AVIV, Israel, May 04, 2017 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (NASDAQ:RDHL) (TASE:RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company primarily focused on the development and commercialization of late clinical-stage, proprietary, orally-administered, small molecule drugs for gastrointestinal and inflammatory dise...
    PDF
    May 3, 2017
    RedHill maintains a debt-free balance sheet with a $61 million cash balance1 at the end of the first quarter of 2017, allowing the Company to continue to diligently execute its development and U.S. commercialization plansSelect recent milestones include: Exclusive U.S. co-promotion agreement for commercial GI drug Donnatal®2 Exclusive licen...
    PDF
    Apr 25, 2017
    TEL-AVIV, Israel, April 25, 2017 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (NASDAQ:RDHL) (Tel-Aviv Stock Exchange:RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company primarily focused on the development and commercialization of late clinical-stage, proprietary, orally-administered, small molecule drugs for gastrointestinal ...
    PDF
    Apr 24, 2017
    Top-line results are expected in the third quarter of 2017  The randomized, double-blind, placebo-controlled Phase II study is evaluating the safety and efficacy of BEKINDA® (RHB-102) 12 mg in 127 U.S. patients with diarrhea-predominant irritable bowel syndrome (IBS-D) IBS is one of the most common gastrointestinal disorders; it is estimated t...
    PDF
    Apr 20, 2017
    The article was authored by scientists from the Medical University of South Carolina (MUSC) Hollings Cancer Center and Apogee Biotechnology and was published in Clinical Cancer ResearchThe Phase I study with YELIVA® in patients with advanced solid tumors successfully met its primary and secondary endpointsResults demonstrated that the drug is ...
    PDF
    Apr 19, 2017
    The R&D Day on BEKINDA® will take place on Thursday, April 27, 2017 in NYC from 8:00-10:00 EDT; A live webcast will be available through RedHill's websiteTop-line results from a Phase III study with BEKINDA® 24 mg for acute gastroenteritis and gastritis are expected in Q2/2017Top-line results from a Phase II study with BEKINDA® 12 mg...
    PDF
    Apr 18, 2017
    RedHill received Notices of Allowance from the United States Patent and Trademark Office (USPTO) for two new patents covering BEKINDA® (RHB-102), expected to be valid until at least 2034, once granted BEKINDA® is a proprietary, bimodal extended-release, once-daily oral pill formulation of ondansetron, targeting several gastrointestinal in...
    PDF
    Apr 13, 2017
    The national marketing approval in Luxembourg completes the current approval process of RIZAPORT® under the European Decentralized Procedure (DCP); RIZAPORT® is also approved for marketing in Germany and a national Marketing Authorization Application (MAA) has been submitted in SpainRIZAPORT® is a proprietary oral thin film formulati...
    PDF
    Apr 5, 2017
    RedHill expects to initiate U.S. promotion of its two commercially-available gastrointestinal specialty products, Donnatal®1 and EnteraGam®2, in mid-2017 Under the terms of the agreement, RedHill will pay Entera Health royalties on net sales generated from the sale of EnteraGam® by RedHill TEL-AVIV, Israel, April 05, 2017 (GLOBE NEW...
    PDF
    Page: FirstPrevious
    3
    ... NextLast

    Subscribe to press releases